financing

News

Myricx founders (l-r) Dr Andrew Bell, Dr Roberto Solari and Professor Ed Tate, with CEO Dr Robin Carr

Myricx raises £90m after pivot to ADCs for cancer

UK biotech Myricx Bio has tapped into the red-hot interest among investors for companies working on antibody-drug conjugates (ADCs) for cancer, raising £90 million ($115 million) in a first

News

Beacon lights up with $170m for retinal disease gene therapy

UK-headquartered Beacon Therapeutics has raised a whopping $170 million in second-round financing that will be used to advance a gene therapy for an inherited cause of blindness through a p

News

David Kendall, chief medical officer at Zealand Pharma

Zealand Pharma rakes in $1bn in funding for obesity drugs

Fresh from reporting encouraging results with its obesity drug candidate petrelintide, Zealand Pharma has raised an impressive $1 billion from a new share offering.

News

EvolutionaryScale emerges with $142m for AI drug discovery

Former Meta researchers working on artificial intelligence (AI) and large language models (LLMs) to find protein drugs have banded together to form a start-up called EvolutionaryScale.

News

Marea’s $190m double round heads latest biotech financings

Our latest round-up of biotech financings includes nine-figure rounds for Marea, Santa Ana Bio, and Opthea, with InduPro, Elion, and iOnctura also in on the action.

News

Telix prices $200m IPO in big week for radiopharma financing

Australian radiopharmaceutical specialist Telix has revealed the terms of its planned initial public offering (IPO) in the US, revealing that it hopes to raise $202 millio

Myricx raises £90m after pivot to ADCs for cancer

Beacon lights up with $170m for retinal disease gene therapy

Zealand Pharma rakes in $1bn in funding for obesity drugs

EvolutionaryScale emerges with $142m for AI drug discovery

Marea’s $190m double round heads latest biotech financings

Telix prices $200m IPO in big week for radiopharma financing

Lilly's 'triple G' retatrutide aces crucial obesity trial

Discover a new era of healthcare panel engagement: Grounded ...

financing

Editor's Picks